<DOC>
	<DOCNO>NCT02807922</DOCNO>
	<brief_summary>Sleep disturbance frequent patient advance cancer decrease tolerability symptom impair quality life . A detailed description sleep disturbance association symptom , intervention study sleep medication scarce patient advanced cancer . A well-designed randomized control trial need determine short time effectiveness zopiclone sleep quality , one currently available therapy insomnia , contribute clinical management insomnia patient advance cancer .</brief_summary>
	<brief_title>Pharmacological Treatment Insomnia Palliative Care</brief_title>
	<detailed_description>The clinical trial randomize , double-blind , placebo control , parallel-group , multicenter trial investigate short time effectiveness zopiclone self-reported sleep quality patient advance cancer use opioids report insomnia . Patients advance cancer use opioids report insomnia randomize either hypnotic , zopiclone ( Arm A ) placebo ( Arm B ) six night . For study zopiclone Actavis 3.75 mg , 5 mg 7.5 mg ( active comparator ) placebo define Investigational Medicinal Products . The initial dose zopiclone/placebo 3.75 mg/day . Evaluation sleep quality perform morning night 2 4 evaluation sleep quality use numerical rating scale 0-10 question `` Please circle number best describes feel '' 0= Best sleep , 10= Worst possible sleep .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Zopiclone</mesh_term>
	<criteria>1 . Histologically verified malignant disease 2 . Presence metastatic / disseminate disease 3 . Presence insomnia syndrome define : 1 . Selfreported difficulty initiate sleep ( great 30 minute sleep onset ) and/or difficulty maintain sleep ( great 30 minute nocturnal waking time ) ; 2 . Sleep difficulty least 3 night per week ; 3 . Sleep difficulty cause significant impairment daytime functioning ( The patient ask sleep difficulty result alter daytime function i.e . feeling tire , lack energy ) 4 . Regularly schedule oral , subcutaneous , transdermal intravenous opioid treatment dose correspond step III WHO pain ladder stable dose least 2 day 5 . Able comply study procedures 6 . Signed informed consent expect cooperation patient treatment follow must obtain document accord ICH GCP , national/local regulation . 1 . Ongoing treatment previous treatment ( within last 4 week ) consecutive 3 day medication give insomnia 2 . Adverse reaction zopiclone 3 . History substance abuse 4 . Concomitant use rifampicin erythromycin 5 . Any contraindication list summary product characteristic investigated medicinal product : 1 . Myasthenia gravis 2 . An establish diagnosis Severe impairment respiratory function 3 . An establish diagnosis Severe hepatic insufficiency . ( ChildPugh grade B C ) 4 . An establish diagnosis sleep apnea 5 . Known hypersensitivity drug component formulation : Lactose monohydrate , Calcium hydrogen phosphate , Maize starch , Croscarmellose sodium , Magnesium stearate , Titanium dioxide ( E 171 ) , Hypromellose , Iron oxide yellow/Iron oxide red ( E 172 ) Macrogol 6 . Unfit participation reason judge investigator 7 . Pregnancy lactation 8 . Women reproductive age willing unable employ effective method contraception ( sterilization , use IUD oral contraception ) 9 . Scheduled surgery within next week 10 . In need change schedule opioid dose baseline ( study visit 1 ) 11 . Scheduled intravenous administration chemotherapy study period ( baseline day 8 ) intravenous administration chemotherapy last week 12 . Change corticosteroid dose last week baseline plan dose change corticosteroid dose within 7 day baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Palliative Care</keyword>
	<keyword>zopiclone</keyword>
</DOC>